- Home
- COHN vs BTAI Comparison
COHN vs BTAI Comparison
Compare COHN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHN
- BTAI
- Stock Information
- Founded
- COHN 1999
- BTAI 2017
- Country
- COHN United States
- BTAI United States
- Employees
- COHN N/A
- BTAI N/A
- Industry
- COHN Investment Bankers/Brokers/Service
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- COHN Finance
- BTAI Health Care
- Exchange
- COHN Nasdaq
- BTAI Nasdaq
- Market Cap
- COHN 20.2M
- BTAI 18.1M
- IPO Year
- COHN N/A
- BTAI 2018
- Fundamental
- Price
- COHN $10.18
- BTAI $0.39
- Analyst Decision
- COHN
- BTAI Buy
- Analyst Count
- COHN 0
- BTAI 4
- Target Price
- COHN N/A
- BTAI $2.81
- AVG Volume (30 Days)
- COHN 6.5K
- BTAI 1.2M
- Earning Date
- COHN 03-05-2025
- BTAI 11-14-2024
- Dividend Yield
- COHN 9.73%
- BTAI N/A
- EPS Growth
- COHN N/A
- BTAI N/A
- EPS
- COHN 2.35
- BTAI N/A
- Revenue
- COHN $89,555,000.00
- BTAI $2,276,000.00
- Revenue This Year
- COHN N/A
- BTAI $164.86
- Revenue Next Year
- COHN N/A
- BTAI $69.74
- P/E Ratio
- COHN $4.38
- BTAI N/A
- Revenue Growth
- COHN 63.18
- BTAI 83.25
- 52 Week Low
- COHN $6.10
- BTAI $0.30
- 52 Week High
- COHN $12.82
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- COHN 46.83
- BTAI 45.86
- Support Level
- COHN $10.13
- BTAI $0.35
- Resistance Level
- COHN $10.65
- BTAI $0.58
- Average True Range (ATR)
- COHN 0.44
- BTAI 0.06
- MACD
- COHN -0.07
- BTAI 0.02
- Stochastic Oscillator
- COHN 45.83
- BTAI 30.65
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.